| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| 2 |
中国医师协会器官移植医师分会，中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版) [J/CD]. 中华移植杂志：电子版，2018, 12(4): 145-150.
|
| 3 |
Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)[J]. J Hepatol, 2012, 57(3): 675-688.
|
| 4 |
Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, et al. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed？[J]. Transplant Proc, 2012, 44(6): 1565-1567.
|
| 5 |
Bina Possatto M, de Ataíde EC, Fazzio Escanhoela CA, et al. Factors related to hepatocellular carcinoma recurrence after liver transplantation-a Brazilian multicenter study[J]. Transplant Proc, 2017, 49(4): 863-866.
|
| 6 |
Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1): 128-139.
|
| 7 |
周俭，肖永胜. 肝癌肝移植临床研究现状与展望[J]. 中国实用外科杂志，2020, 40(1): 37-41.
|
| 8 |
Vatansever S, Farajov R, Yılmaz HC, et al. Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria[J]. Turk J Gastroenterol, 2019, 30(1): 75-80.
|
| 9 |
Wu L, Yang F, Lin B, et al. MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation[J]. Oncol Lett, 2018, 15(6): 9126-9132.
|
| 10 |
Pan Y, Chen H, Yu J. Biomarkers in hepatocellular carcinoma: current status and future perspectives[J]. Biomedicines, 2020, 8(12): 576.
|
| 11 |
Trevisan França de Lima L, Broszczak D, Zhang X, et al. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874(2): 188451.
|
| 12 |
Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol, 2017, 14(9): 531-548.
|
| 13 |
Kilgour E, Rothwell DG, Brady G, et al. Liquid biopsy-based biomarkers of treatment response and resistance[J]. Cancer Cell, 2020, 37(4): 485-495.
|
| 14 |
Xu W, Cao L, Chen L, et al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy[J]. Clin Cancer Res, 2011, 17(11): 3783-3793.
|
| 15 |
吉翔，杨艳丽，汪亚辉，等. 循环肿瘤细胞检测技术在胃癌诊治中应用的研究进展[J]. 现代肿瘤医学，2018, 26(8): 1303-1307.
|
| 16 |
Sun YF, Xu Y, Yang XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468.
|
| 17 |
Wang S, Zheng Y, Liu J, et al. Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation[J]. J Investig Med, 2018, 66(5): 1-6.
|
| 18 |
Court CM, Hou S, Winograd P, et al. A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma[J]. Liver Transpl, 2018, 24(7): 946-960.
|
| 19 |
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238.
|
| 20 |
García-Fernández N, Macher HC, Rubio A, et al. Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a biomarker of tumor recurrence[J]. Adv Exp Med Biol, 2016, 924: 25-28.
|
| 21 |
Krenzien F, Katou S, Papa A, et al. Increased cell-free DNA plasma concentration following liver transplantation is linked to portal hepatitis and inferior survival[J]. J Clin Med, 2020, 9(5): 1543.
|
| 22 |
Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7(26): 40481-40490.
|
| 23 |
Cai ZX, Chen G, Zeng YY, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985.
|
| 24 |
Zhang HM, Shi YX, Sun LY, et al. Hepatocellular carcinoma recurrence in living and deceased donor liver transplantation: a systematic review and meta-analysis[J]. Chin Med J (Engl), 2019, 132(13): 1599-1609.
|
| 25 |
Wen Y, Han J, Chen J, et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma[J]. Int J Cancer, 2015, 137(7): 1679-1690.
|
| 26 |
Farid WR, Verhoeven CJ, de Jonge J, et al. The ins and outs of microRNAs as biomarkers in liver disease and transplantation[J]. Transpl Int, 2014, 27(12): 1222-1232.
|
| 27 |
Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma[J]. Clin Chim Acta, 2020, 500: 10-19.
|
| 28 |
Morita K, Shirabe K, Taketomi A, et al. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation[J]. Liver Transpl, 2016, 22(5): 665-676.
|
| 29 |
Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation[J]. Oncotarget, 2016, 7(15): 19824-19839.
|
| 30 |
Shang W, Adzika GK, Li Y, et al. Molecular mechanisms of circular RNAs, transforming growth factor-β，and long noncoding RNAs in hepatocellular carcinoma[J]. Cancer Med, 2019, 8(15): 6684-6699.
|
| 31 |
Yuan D, Chen Y, Li X, et al. Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis[J]. Int J Biol Sci, 2021, 17(1): 220-235.
|
| 32 |
Wu L, Yang Z, Zhang J, et al. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation[J]. Hepatobiliary Surg Nutr, 2018, 7(6): 429-439.
|
| 33 |
Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation[J]. Med Oncol, 2012, 29(3): 1810-1816.
|
| 34 |
Agopian VG, Harlander-Locke M, Zarrinpar A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427.
|
| 35 |
Foerster F, Hoppe-Lotichius M, Vollmar J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849.
|
| 36 |
Özdemir F, Baskiran A. The importance of AFP in liver transplantation for HCC[J]. J Gastrointest Cancer, 2020, 51(4): 1127-1132.
|
| 37 |
Nielsen MJ, Villesen IF, Gudmann NS, et al. Serum markers of type Ⅲ and Ⅳ procollagen processing predict recurrence of fibrosis in liver transplanted patients[J]. Sci Rep, 2019, 9(1): 14857.
|
| 38 |
Hayashi M, Yamada S, Tanabe H, et al. High serum uric acid levels could be a risk factor of hepatocellular carcinoma recurrences[J]. Nutr Cancer, 2021, 73(6): 996-1003.
|
| 39 |
Li Y, Xu W, Chen P, et al. Correlation analysis between preoperative serum iron level and prognosis as well as recurrence of HCC after radical resection[J]. Cancer Manag Res, 2020, 12: 31-41.
|
| 40 |
Cai H, Zhang Y, Meng F, et al. Preoperative serum IL6, IL8, and TNF-α may predict the recurrence of hepatocellular cancer[J]. Gastroenterol Res Pract, 2019: 6160783.
|